avobenzone; octinoxate; oxybenzone - Profile

What are the generic drug sources for avobenzone; octinoxate; oxybenzone and what is the scope of freedom to operate?

Avobenzone; octinoxate; oxybenzone is the generic ingredient in one branded drug marketed by Bayer Healthcare Llc and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for avobenzone; octinoxate; oxybenzone

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for avobenzone; octinoxate; oxybenzone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare Llc	SHADE UVAGUARD	avobenzone; octinoxate; oxybenzone	LOTION;TOPICAL	020045-001	Dec 7, 1992		DISCN	Yes	No

Expired US Patents for avobenzone; octinoxate; oxybenzone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Healthcare Llc	SHADE UVAGUARD	avobenzone; octinoxate; oxybenzone	LOTION;TOPICAL	020045-001	Dec 7, 1992
Bayer Healthcare Llc	SHADE UVAGUARD	avobenzone; octinoxate; oxybenzone	LOTION;TOPICAL	020045-001	Dec 7, 1992

Investment Scenario and Fundamentals Analysis: Avobenzone, Octinoxate, Oxybenzone

Last updated: April 25, 2026

What is the market structure for these UV filters?

Avobenzone, octinoxate, and oxybenzone (benzophenone-3) are UV filters used in sunscreen and personal care products. The investment thesis for each ingredient depends on (1) regulatory acceptance in key geographies, (2) substitution risk from newer filters, and (3) supply-chain concentration and backward integration by large formulators.

Commercially relevant positioning

• Avobenzone: UVA filter. Markets it through broad UVA coverage and formulary flexibility. It is widely used globally but faces stability and photodegradation management requirements, typically solved by formulary stabilization and film-former approaches.
• Octinoxate: UVB filter. It is heavily used in spray and liquid sunscreen formats where cost and sensorial properties matter.
• Oxybenzone (benzophenone-3): Broad-market UV filter with established global history. It has materially higher regulatory and brand risk in several jurisdictions relative to avobenzone and octinoxate.

Demand drivers that tie to investment

• Climate and skincare penetration: sunscreen usage volumes track heat exposure and consumer skin-health trends.
• Product format mix: higher share of sprays, sticks, and leave-on formats increases consumption per unit area.
• Regulatory compliance: ingredient inclusion controls end-product market access.

How do regulations shape investable demand?

These ingredients face different regulatory outcomes by region, which directly affects profitable volume and pricing power.

United States

• Oxybenzone: Not approved for OTC sunscreen in the U.S. (FDA status for OTC sunscreen drug ingredients excludes oxybenzone as an active ingredient). This constrains U.S. demand to non-OTC or non-sunscreen applications and materially caps mainstream consumer sunscreen exposure.
• Avobenzone and octinoxate: Both are permitted as active ingredients in OTC sunscreen in the U.S. under current FDA frameworks, supporting baseline demand.

Investment implication

• U.S. exposure is structurally favorable for avobenzone and octinoxate, materially unfavorable for oxybenzone.

European Union

The EU is governed by the Cosmetics Regulation (EU) No 1223/2009 and Annexes listing allowed UV filters with permitted concentration limits.

• Oxybenzone (benzophenone-3): Has historically faced restrictions and bans in several EU member states and is subject to evolving regulatory scrutiny at EU level across cycles. This is consistent with the broader EU shift toward filters with lower safety or environmental concerns.
• Avobenzone and octinoxate: Are positioned as permitted UV filters, with concentration limits and formulation constraints.

Investment implication

• Oxybenzone carries higher country-level and product form variability across Europe.
• Avobenzone and octinoxate retain more predictable access in EU sunscreen categories.

Key risk axis: environmental scrutiny

• Oxybenzone has higher exposure to brand and regulatory restrictions tied to environmental effects compared with many alternative UV filters.
• The market has moved toward “new generation” filters in some segments, increasing substitution pressure on oxybenzone.

What is the substitution risk versus newer UV filters?

Across sunscreen portfolios, formulators increasingly adopt alternative UV filters that meet safety, stability, and regulatory status in each jurisdiction.

Substitution dynamics by filter type

• UVA filters: Avobenzone competes with newer UVA filters (and combinations that stabilize UVA coverage). Avobenzone’s substitution risk is real but mitigated by its established performance and available stabilization systems.
• UVB filters: Octinoxate faces competition from other UVB agents, but cost and solvency compatibility keep it relevant in mainstream price tiers.
• Oxybenzone: Substitution risk is structurally higher because several markets do not allow or restrict it, pushing formulators to replace it when building compliant product lines.

Investment implication

• The cleanest investable demand baseline is usually with avobenzone and octinoxate.
• Oxybenzone behaves more like a constrained ingredient with higher policy and brand volatility.

What is the patent and IP landscape risk for an investable supply chain?

Avobenzone, octinoxate, and oxybenzone are long-established actives with mature manufacturing knowledge and chemical synthesis routes. For pure-ingredient investing, the critical IP is less about “composition-of-matter” and more about:

• Process improvements (yield, impurities, scalable purification).
• Photostability and formulation systems (where relevant for suppliers tied to branded intermediates).
• Regulatory dossiers and compliance packages (not always patent-protected, but operationally defensible).

Investment implication

• Ingredient-level margins often revert to commodity-like levels unless a supplier has (1) proprietary low-cost process control, (2) captive supply, or (3) regulatory access advantages in key jurisdictions.

Who holds bargaining power across the value chain?

UV filter economics depend on bargaining power at three layers:

1. Chemical manufacturers and intermediate suppliers
   • Control supply continuity and compliance quality.
2. Formulators and finished product manufacturers
   • Control inclusion and concentration based on SPF/PA targets, sensorial constraints, and regulatory constraints.
3. Large retailers and branded skincare companies
   • Control demand via procurement and private label specifications.

Bargaining power map (practical)

• Where an active is restricted or banned (notably for oxybenzone in some major channels), formulators increase purchasing power scarcity risk for the remaining compliant supply chain.
• Where the active is permitted and has multiple approved suppliers (notably for avobenzone and octinoxate), price competition increases.

What are the key fundamentals that drive ingredient-level margins?

The fundamentals are consistent across UV filters, with different intensity by ingredient.

1) Regulatory clearance and listing stability

• Avobenzone and octinoxate generally offer better clearance stability for mainstream sunscreen.
• Oxybenzone is more exposed to removal or restriction decisions, which shortens the revenue runway and increases inventory and compliance risk.

2) Manufacturing scale and impurity control

UV filters require tight impurity specifications for cosmetics compliance. Suppliers with validated quality systems and high batch success rates command better reliability premiums.

3) Formulation dependence

• Avobenzone often depends on stabilization systems to maintain performance after application.
• Octinoxate is simpler from a photostability standpoint but still competes on sensory and volatility.
• Oxybenzone’s performance is known, but its inclusion is the limiting factor more often than performance.

4) Substitute availability

• The more available alternative UV filters are in a region, the faster margins mean-revert.
• Oxybenzone faces stronger practical substitution due to compliance and brand constraints.

How should an investor frame the investment scenario?

Base-case portfolio logic

• Prefer avobenzone and octinoxate exposure for volume durability tied to broad regulatory acceptance.
• Treat oxybenzone as a constrained exposure where the investable case relies on non-mainstream channels, existing contracts, legacy inventories, or specific compliant formulation niches.

Catalyst calendar (what matters operationally)

• Regulatory announcements: Changes to permitted filters or concentration limits can rapidly shift demand.
• Retail SKU mix changes: Growth in specific sunscreen formats changes per-unit consumption.
• Large corporate procurement cycles: Sourcing can lock in volume for months, affecting realized prices.

What are the practical “fundamentals scorecards” by ingredient?

Avobenzone

Positive fundamentals

• UVA coverage with broad historic use.
• Generally permitted in major sunscreen markets.
• Stabilization technology ecosystem reduces formulation risk.

Investment watch items

• Photostability and performance requirements force formulators into stabilization systems that can dilute raw ingredient margin in some value chains.
• UVA filter substitution cycles occur when new filters gain share.

Octinoxate

Positive fundamentals

• Broad UVB filter use with extensive formulation familiarity.
• Generally permitted in major sunscreen markets.
• Cost and compatibility with common sunscreen bases support ongoing demand.

Investment watch items

• UVB filter substitution pressure depends on region-specific regulatory and consumer acceptance.
• Price competition likely remains high where supply is diversified.

Oxybenzone

Negative-to-neutral fundamentals

• Higher restriction and non-approval risk in major OTC sunscreen frameworks.
• Higher brand and environmental scrutiny drives replacement.

Investment watch items

• Any incremental regulatory relaxation could temporarily support demand, but the base case is constrained.
• Substitution is more direct because many brands can switch to compliant alternatives with minimal performance compromise.

What does this imply for business actions and sourcing strategy?

For companies investing in or allocating capital to these UV filters, the most actionable operating decisions typically track to three levers:

1. Compliance-first capacity planning
   • Prioritize products and batch validation that map directly to active regulatory markets.
2. Customer qualification for stability and impurity specs
   • Lock in stable supply relationships with formulators by hitting tight quality windows.
3. Positioning by channel
   • Avobenzone and octinoxate align to mainstream sunscreen.
   • Oxybenzone aligns to narrower niches or non-standard product categories, if any.

Key Takeaways

• Avobenzone and octinoxate are structurally better positioned for mainstream sunscreen demand because they are generally permitted as active UV filters in major markets, supporting more durable volume.
• Oxybenzone carries materially higher restriction risk, creating a shorter and more volatile demand runway and increasing substitution pressure.
• Ingredient-level investment success is less about novel patents and more about regulatory access, supply reliability, and quality/impurity control.
• The most defensible strategy is core allocation to avobenzone and octinoxate with tactical or limited exposure to oxybenzone, aligned to specific channel, contract, or compliance niches.

FAQs

1. Which of the three UV filters has the weakest U.S. sunscreen pathway?
   Oxybenzone.

2. Which two are the more investable targets for mainstream sunscreen volumes?
   Avobenzone and octinoxate.

3. What most directly drives ingredient demand versus consumer marketing?
   Regulatory permission status and concentration limits in key geographies.

4. Why can avobenzone still hold relevance despite substitution risk?
   Its entrenched UVA coverage role and the stabilization ecosystem that supports shelf and on-skin performance.

5. What operational factor most often protects margins in UV filters?
   Batch-to-batch impurity control and compliance readiness that reduce customer rejections and qualify suppliers faster.

---

References

[1] U.S. Food and Drug Administration. (2023). Over-the-counter (OTC) sunscreen drug products for over-the-counter human use; final rule and supporting documents. https://www.fda.gov/
[2] European Commission. (2009). Regulation (EC) No 1223/2009 on cosmetic products. https://eur-lex.europa.eu/
[3] European Chemicals Agency (ECHA). (n.d.). Substance information and regulatory status for benzophenone-3 (oxybenzone) and related UV filters. https://echa.europa.eu/